Barclays PLC lifted its stake in shares of Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) by 171.1% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 159,241 shares of the company's stock after acquiring an additional 100,498 shares during the quarter. Barclays PLC owned about 0.10% of Wave Life Sciences worth $1,307,000 as of its most recent filing with the SEC.
Several other large investors also recently made changes to their positions in the stock. Maverick Capital Ltd. boosted its stake in Wave Life Sciences by 31.0% during the 3rd quarter. Maverick Capital Ltd. now owns 10,047,520 shares of the company's stock valued at $82,390,000 after purchasing an additional 2,378,159 shares during the period. Emerald Advisers LLC lifted its position in shares of Wave Life Sciences by 15.6% in the 3rd quarter. Emerald Advisers LLC now owns 2,881,510 shares of the company's stock worth $23,628,000 after acquiring an additional 388,280 shares during the period. State Street Corp lifted its position in shares of Wave Life Sciences by 2.6% in the 3rd quarter. State Street Corp now owns 2,321,248 shares of the company's stock worth $19,034,000 after acquiring an additional 57,822 shares during the period. Geode Capital Management LLC lifted its position in shares of Wave Life Sciences by 14.3% in the 3rd quarter. Geode Capital Management LLC now owns 2,269,664 shares of the company's stock worth $18,615,000 after acquiring an additional 283,419 shares during the period. Finally, Emerald Mutual Fund Advisers Trust lifted its position in shares of Wave Life Sciences by 16.6% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 2,123,466 shares of the company's stock worth $17,412,000 after acquiring an additional 302,528 shares during the period. Institutional investors own 89.73% of the company's stock.
Wave Life Sciences Trading Down 2.3 %
Shares of NASDAQ:WVE traded down $0.27 during midday trading on Monday, hitting $11.27. The company had a trading volume of 1,283,962 shares, compared to its average volume of 1,031,652. Wave Life Sciences Ltd. has a 12 month low of $3.50 and a 12 month high of $16.74. The stock has a market cap of $1.72 billion, a price-to-earnings ratio of -10.15 and a beta of -1.07. The firm has a fifty day simple moving average of $14.03 and a 200 day simple moving average of $9.78.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently issued reports on WVE shares. Leerink Partners increased their target price on Wave Life Sciences from $20.00 to $22.00 and gave the stock an "outperform" rating in a report on Wednesday, October 16th. Raymond James raised Wave Life Sciences from an "outperform" rating to a "strong-buy" rating and increased their target price for the stock from $13.00 to $22.00 in a report on Wednesday, October 16th. Royal Bank of Canada raised their price target on Wave Life Sciences from $7.00 to $15.00 and gave the company a "sector perform" rating in a report on Monday, October 21st. StockNews.com cut Wave Life Sciences from a "hold" rating to a "sell" rating in a report on Wednesday, November 13th. Finally, Mizuho raised their price target on Wave Life Sciences from $19.00 to $22.00 and gave the company an "outperform" rating in a report on Thursday, November 21st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $22.22.
Get Our Latest Research Report on WVE
Insider Transactions at Wave Life Sciences
In other Wave Life Sciences news, CEO Paul Bolno sold 50,000 shares of Wave Life Sciences stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $15.00, for a total transaction of $750,000.00. Following the transaction, the chief executive officer now directly owns 217,351 shares in the company, valued at approximately $3,260,265. The trade was a 18.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Chris Francis sold 36,000 shares of Wave Life Sciences stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $576,000.00. The disclosure for this sale can be found here. Insiders have sold 436,544 shares of company stock worth $6,271,569 in the last three months. Insiders own 29.10% of the company's stock.
About Wave Life Sciences
(
Free Report)
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
Read More
Before you consider Wave Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Wave Life Sciences wasn't on the list.
While Wave Life Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
